B1

MF & Co Launches New Index Analytics Portal For CRTx® Index

Retrieved on: 
Wednesday, August 23, 2023
Software, Finance, Artificial Intelligence, Banking, Data Management, Professional Services, Technology, Fintech, Transfer, Configurator, Intelligence, MF, Index, Suite, Fontanilla, Cryptocurrency, Publishing, B1

Mark Fontanilla & Co., LLC (MF & Co) announced today the launch of its advanced index analytics digital platform, the CRTx® Index Portal, for the company’s flagship CRTx® (Credit Risk Transfer Return Tracking Index) Index Suite.

Key Points: 
  • Mark Fontanilla & Co., LLC (MF & Co) announced today the launch of its advanced index analytics digital platform, the CRTx® Index Portal, for the company’s flagship CRTx® (Credit Risk Transfer Return Tracking Index) Index Suite.
  • With this new portal, the company is also adding index variations to its comprehensive CRTx® bond index family, in addition to introducing a flat fee structure for benchmark index licensing.
  • In conjunction with the launch, MF & Co is introducing several other product updates:
    New M1, M2, B1, B2, & B bond class index configurations have been added to the CRTx® Index Suite, and are only available via the CRTx® Index Portal.
  • “The CRTx® Index Portal provides the ability to get faster, more dynamic insights into index performance than ever before.

Lepro Unveils World's Leading AI Lighting, LightGPT™, The Lighting Industry's "ChatGPT"

Retrieved on: 
Monday, August 21, 2023
Lighting, Music, Photograph, Alexa, Light, Human, Emotion, Amazon, AI, B1, Mobile phone, Nightclub, EU, Sargocentron lepros

A keystone of Lepro technologies, the proprietary LightGPT™ offers users an AI-driven lighting experience, recommending light effects in real-time to voice commands and photographic cues.

Key Points: 
  • A keystone of Lepro technologies, the proprietary LightGPT™ offers users an AI-driven lighting experience, recommending light effects in real-time to voice commands and photographic cues.
  • Through the Lepro app, users can input a photograph or vocalize their current emotional state to access self-generative lighting effects.
  • Lepro B1 goes beyond traditional lighting by matching your home lighting to your mood.
  • Simply snap a selfie, upload it on the Lepro app, or express your mood verbally to enjoy personalized lighting that reflects how you feel.

Lepro Unveils World's Leading AI Lighting, LightGPT™, The Lighting Industry's "ChatGPT"

Retrieved on: 
Monday, August 21, 2023
Lighting, Music, Photograph, Alexa, Light, Human, Emotion, Amazon, AI, B1, Mobile phone, Nightclub, EU, Sargocentron lepros

A keystone of Lepro technologies, the proprietary LightGPT™ offers users an AI-driven lighting experience, recommending light effects in real-time to voice commands and photographic cues.

Key Points: 
  • A keystone of Lepro technologies, the proprietary LightGPT™ offers users an AI-driven lighting experience, recommending light effects in real-time to voice commands and photographic cues.
  • Through the Lepro app, users can input a photograph or vocalize their current emotional state to access self-generative lighting effects.
  • Lepro B1 goes beyond traditional lighting by matching your home lighting to your mood.
  • Simply snap a selfie, upload it on the Lepro app, or express your mood verbally to enjoy personalized lighting that reflects how you feel.

Estar Medical: The European Patent Office Revokes Two Regenlab PRP Patents

Retrieved on: 
Monday, January 23, 2023
PRP, Case Law of the Boards of Appeal of the European Patent Office, Opposition, High Court of Justice, Judgement, EPO, United Kingdom, European Patent Convention, Patent, B1, Regenerative medicine, Opposition procedure before the European Patent Office, Growth, Hearing, Generic drug

HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Estar Medical® has been successful in revoking Regenlab's original patent for making platelet rich plasma (PRP) at the European Patent Office (EPO).

Key Points: 
  • HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Estar Medical® has been successful in revoking Regenlab's original patent for making platelet rich plasma (PRP) at the European Patent Office (EPO).
  • This ruling follows an earlier decision this month by the Opposition Division of the EPO revoking a different Regenlab PRP patent, as well as a recent judgment by the UK Courts which held the original Regenlab PRP patent to be invalid for lack of novelty and inventive step.
  • Estar Technologies Ltd. ("Estar Medical") today announced that on January 10, 2023, the Board of Appeal of the EPO has officially revoked Regen Lab SA ("Regenlab") platelet rich plasma (PRP) patent for lack of inventive step.
  • Earlier this month, on January 4, 2023, the Opposition Division of the EPO revoked another Regenlab PRP patent, European Patent No 3111974 B1 relating to blood collection tubes for the preparation of PRP.

Estar Medical: The European Patent Office Revokes Two Regenlab PRP Patents

Retrieved on: 
Monday, January 23, 2023
PRP, Case Law of the Boards of Appeal of the European Patent Office, Opposition, High Court of Justice, Judgement, EPO, United Kingdom, European Patent Convention, Patent, B1, Regenerative medicine, Opposition procedure before the European Patent Office, Growth, Hearing, Generic drug

HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Estar Medical® has been successful in revoking Regenlab's original patent for making platelet rich plasma (PRP) at the European Patent Office (EPO).

Key Points: 
  • HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Estar Medical® has been successful in revoking Regenlab's original patent for making platelet rich plasma (PRP) at the European Patent Office (EPO).
  • This ruling follows an earlier decision this month by the Opposition Division of the EPO revoking a different Regenlab PRP patent, as well as a recent judgment by the UK Courts which held the original Regenlab PRP patent to be invalid for lack of novelty and inventive step.
  • Estar Technologies Ltd. ("Estar Medical") today announced that on January 10, 2023, the Board of Appeal of the EPO has officially revoked Regen Lab SA ("Regenlab") platelet rich plasma (PRP) patent for lack of inventive step.
  • Earlier this month, on January 4, 2023, the Opposition Division of the EPO revoked another Regenlab PRP patent, European Patent No 3111974 B1 relating to blood collection tubes for the preparation of PRP.

EQS-News: Cryptology’s estimated NAV per share as of 09/11/2022 is €4.60

Retrieved on: 
Friday, November 11, 2022
Share repurchase, ISIN, News, NAV, HPC, XETRA, Cryptography, Tradegate Exchange, B1, Security (finance), Cryptocurrency

Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.60.

Key Points: 
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.60.
  • In August, Cryptologys shares were listed on electronic trading venue, Xetra, Germanys leading trading venue for listed companies.
  • Cryptologys listing on Xetra comes on the heels of the recent news that Cryptology had begun a share buyback program in July.
  • Cryptologys updated estimated NAV figures come on the heels of Hauck & Aufhuser issuing an updated report on Cryptologys shares with a BUY rating and a price target of 5.50.

EQS-News: Cryptology’s estimated NAV per share as of 26/10/2022 is €4.89

Retrieved on: 
Friday, October 28, 2022
NAV, Share repurchase, B1, ISIN, Cryptography, News, HPC, XETRA, Tradegate Exchange, Security (finance), Cryptocurrency

Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.89.

Key Points: 
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.89.
  • In August, Cryptologys shares were listed on electronic trading venue, Xetra, Germanys leading trading venue for listed companies.
  • Cryptologys listing on Xetra comes on the heels of the recent news that Cryptology had begun a share buyback program in July.
  • Cryptologys updated estimated NAV figures come on the heels of Hauck & Aufhuser issuing an updated report on Cryptologys shares with a BUY rating and a price target of 5.50.

EQS-News: Cryptology’s estimated NAV per share as of 19/10/2022 is €4.88

Retrieved on: 
Saturday, October 22, 2022
News, Share repurchase, ISIN, HPC, NAV, Cryptography, XETRA, B1, Tradegate Exchange, Security (finance), Cryptocurrency

Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.88.

Key Points: 
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 4.88.
  • In August, Cryptologys shares were listed on electronic trading venue, Xetra, Germanys leading trading venue for listed companies.
  • Cryptologys listing on Xetra comes on the heels of the recent news that Cryptology had begun a share buyback program in July.
  • Cryptologys updated estimated NAV figures come on the heels of Hauck & Aufhuser issuing an updated report on Cryptologys shares with a BUY rating and a price target of 5.50.

EQS-News: Cryptology’s estimated NAV per share as of 05/10/2022 is €5.03

Retrieved on: 
Thursday, October 6, 2022
News, Share repurchase, ISIN, HPC, NAV, Cryptography, XETRA, B1, Tradegate Exchange, Security (finance), Cryptocurrency

Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 5.03.

Key Points: 
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 5.03.
  • In August, Cryptologys shares were listed on electronic trading venue, Xetra, Germanys leading trading venue for listed companies.
  • Cryptologys updated estimated NAV figures come on the heels of Hauck & Aufhuser issuing an updated report on Cryptologys shares with a BUY rating and a price target of 5.50.
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR) is a leading European holding company for crypto assets and blockchain-based business models.

EQS-News: Cryptology’s estimated NAV per share as of 28/09/2022 is €5.08

Retrieved on: 
Thursday, September 29, 2022
ISIN, EBITDA, NAV, News, Tradegate Exchange, Share repurchase, B1, EUR, KPMG, HPC, XETRA, Mission statement, Security (finance), Cryptocurrency, Cryptography

Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 5.08.

Key Points: 
  • Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European holding company for crypto assets and blockchain-related business models, announced its most recent weekly estimated Net Asset Value (NAV) per share of 5.08.
  • Northern Data reported a significant increase overall, with revenue up to EUR 189.9 million and EBITDA of EUR 320.1 million.
  • In August, Cryptologys shares were listed on electronic trading venue, Xetra, Germanys leading trading venue for listed companies.
  • Cryptologys updated estimated NAV figures come on the heels of Hauck & Aufhuser issuing an updated report on Cryptologys shares with a BUY rating and a price target of 5.50.